Initial Statement of Beneficial Ownership (3)
October 01 2021 - 4:09PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lis William |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/24/2021
|
3. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [JSPR]
|
(Last)
(First)
(Middle)
2200 BRIDGE PKWY SUITE #102 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Executive Officer / |
(Street)
REDWOOD CITY, CA 94065
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | (1) | 5/31/2030 | Common Stock | 730850 | $0.71 | D | |
Stock Option (right to buy) | (2) | 9/2/2030 | Common Stock | 229095 | $0.71 | D | |
Explanation of Responses: |
(1) | 50% of the original number of shares subject to the option were vested as of June 1, 2020, the date of grant; 5% of the original number of shares subject to the option vested on June 21, 2020 and monthly thereafter through and including November 21, 2020; and 1.66% of the original number of shares subject to the option vested on December 21, 2020 and have vested and shall vest monthly thereafter through and including November 21, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
(2) | 1/18th of the original number of shares subject to the option vested on September 3, 2020, and 1/18th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Remarks: Exhibit 24 - Power of Attorney |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Lis William 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY, CA 94065 | X |
| Chief Executive Officer |
|
Signatures
|
By: /s/ Jeet Mahal, as Attorney-in-Fact | | 10/1/2021 |
**Signature of Reporting Person | Date |
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Sep 2023 to Sep 2024